secwatch.observer — SEC 8-K summary
======================================

Issuer:     SCYNEXIS INC (SCYX)
CIK:        0001178253
Form:       8-K
Filed at:   2022-05-12T23:59:59+00:00
Accession:  0001564590-22-019835
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

SCYNEXIS Q1 net loss $5.5M; BREXAFEMME sales $0.7M; CANDLE study positive for rVVC
--------------------------------------------------------------------------------

- Net loss $5.5M ($0.17/share) vs $4.7M ($0.18) in Q1 2021; product revenue $0.7M from BREXAFEMME.
- Cash $95.2M at March 31; plus $42M net from April offering; runway into Q1 2024.
- BREXAFEMME: ~4,000 prescriptions Q1, 1,800 HCPs; 55% commercial coverage (93M lives).
- CANDLE Phase 3 met endpoint: 65.4% vs 53.1% placebo (p=0.02) for rVVC prevention; sNDA planned Q2 2022.
- MARIO global Phase 3 initiated for invasive candidiasis; first patient enrollment expected Q2 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1178253/000156459022019835/0001564590-22-019835-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1178253/000156459022019835/scyx-8k_20220512.htm
  HTML page:      https://secwatch.observer/filing/0001564590-22-019835

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer